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Abstract
Background: The milk fat globule membrane (MFGM) is primarily composed of polar phospho- and sphingolipids,
which have established biological effects on neuroplasticity. The present study aimed to investigate the effect of
dietary MFGM supplementation on the neuromuscular system during post-natal development.
Methods: Growing rats received dietary supplementation with bovine-derived MFGM mixtures consisting of
complex milk lipids (CML), beta serum concentrate (BSC) or a complex milk lipid concentrate (CMLc) (which lacks
MFGM proteins) from post-natal day 10 to day 70.
Results: Supplementation with MFGM mixtures enriched in polar lipids (BSC and CMLc, but not CML)
increased the plasma phosphatidylcholine (PC) concentration, with no effect on plasma phosphatidylinositol
(PI), phosphatidylethanolamine (PE), phosphatidylserine (PS) or sphingomyelin (SM). In contrast, muscle PC was
reduced in rats receiving supplementation with both BSC and CMLc, whereas muscle PI, PE, PS and SM
remained unchanged. Rats receiving BSC and CMLc (but not CML) displayed a slow-to-fast muscle fibre type
profile shift (MyHCI→MyHCIIa) that was associated with elevated expression of genes involved in myogenic
differentiation (myogenic regulatory factors) and relatively fast fibre type specialisation (Myh2 and Nfatc4).
Expression of neuromuscular development genes, including nerve cell markers, components of the
synaptogenic agrin–LRP4 pathway and acetylcholine receptor subunits, was also increased in muscle of rats
supplemented with BSC and CMLc (but not CML).
Conclusions: These findings demonstrate that dietary supplementation with bovine-derived MFGM mixtures
enriched in polar lipids can promote neuromuscular development during post-natal growth in rats, leading to
shifts in adult muscle phenotype.
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Background
Skeletal muscle tissue comprises a spectrum of muscle
fibre types that differ in structure, molecular composition
and functional properties [1, 2]. The fibre type profile of a
given muscle is initially established during embryonic
development, independently of neural influences, by the
differentiation of distinct myoblast lineages, which are
committed to form different myofibre type populations
[2, 3]. However, nerve activity subsequently plays a
major role in the maintenance and modulation of the
muscle fibre type profile during early post-natal devel-
opment and throughout adult life [4–6]. Muscle fibre
characteristics may be altered, changing size and transi-
tioning from a fast-to-slow or a slow-to-fast fibre type
profile both during normal post-natal development and
in the adult organism in response to exercise, disuse
and ageing [6–9]. Nutrition is an additional known, but
less well understood, determinant of muscle fibre type
profile [8].
Early post-natal life is a period of heightened neuro-
muscular plasticity, in which marked morphological
changes occur in pre- and post-synaptic components of
the neuromuscular junction (NMJ) [10]. These changes
coincide with shifts in muscle fibre type profile as spe-
cific muscles develop their adult phenotype [2]. During
embryonic development, acetylcholine (ACh) receptors
(AChRs) accumulate in a broad band in the middle por-
tion of the myofibre and extensive innervation occurs,
generating polyinnervated NMJs with large motor units
[11]. Subsequent maturation of the NMJ during post-
natal development involves extensive reorganisation of
pre- and post-synaptic morphology and a removal of
surplus axonal terminals at polyinnervated NMJs. The
compound agrin, released from pre-synaptic axon nerve
terminals, plays a key role in NMJ maturation during
post-natal development by stimulating clustering and
aggregation of AChRs on the muscle fibre membrane.
Multiple alternatively spliced forms of agrin that differ
in their binding characteristics and bioactivity are syn-
thesized by both nerve and muscle cells [12]. Neurons
specifically express splice variants of agrin (Z+ isoforms)
which include sequences encoded by the alternate exons
32 and/or 33 [12, 13]). Notably, these Z+ isoforms are
1,000-fold more active than those lacking Z exons (Z−
isoforms) in inducing aggregation of AChR clusters at
the NMJ [14]. Synaptic agrin is cleaved and inactivated
by neurotrypsin, resulting in the release of C-terminal
agrin fragments (CAFs). Plasma CAFs have been found
to be elevated in a subset of human sarcopenia patients,
suggesting that uncontrolled degradation of agrin at the
NMJ may contribute to age-associated neuromuscular
decline [15–18]. Similarly, overexpression of neurotryp-
sin resulted in a precocious sarcopenic phenotype that
was characterised by weakness, NMJ fragmentation and
pathological muscle abnormalities (termed SARCO mice)
[19]. Administration of a recombinant neurotrypsin-
resistant form of agrin has been shown to improve muscle
pathology by minimising the disassembly of the NMJ in
SARCO mice [20]. Therefore, modulation of muscle agrin
signalling and/or NMJs may be a novel treatment of
sarcopenia and neuromuscular disease.
Milk is the main source of nutrition in newborn mam-
mals. It also contains a number of minor constituents that
possess potential bioactivity beyond their pure nutritional
significance [21, 22]. Milk fat is secreted as lipid droplets
consisting of a hydrophobic triglyceride core enclosed
within a thin membrane that is composed of a lipid and
protein trilayer and is known as the milk fat/lipid globule
membrane (MFGM) [22]. The MFGM contains polar
lipids including phospholipids (PLs) [phosphatidylserine
(PS), phosphatidylcholine (PC), phosphatidylethanolamine
(PE), phosphatidylinositol (PI)], sphingolipids [sphingo-
myelin (SM)] and gangliosides (GM3 and GD3) [21–23].
Although PLs and sphingolipids represent only 0.5–1% of
the total lipids in milk, there is considerable interest in
these compounds due to their potential bioactivity and
because several health-promoting effects have been attrib-
uted to MFGM composites [21, 22, 24, 25]. In particular,
MFGM composites including PLs [24], sphingolipids
[26, 27] and gangliosides [28–30] have purported positive
effects on neuroplasticity. For example, dietary supplemen-
tation with bovine-derived MFGM mixtures has recently
been reported to promote post-natal neurodevelopment
[31–35] and to limit age-associated neural decline in eld-
erly animals [36].
Given the close relationship between nerve and muscle,
MFGM supplementation may have potential to indirectly
influence muscle tissue, secondary to effects on neuroplas-
ticity. Additionally, components enriched in the MFGM,
including PLs and sphingolipids, have recently been impli-
cated as molecules that play an important direct positive
role in muscle cell growth and development [37–39]. In a
recent study, combined habitual exercise and dietary sup-
plementation with a bovine-derived MFGM supplement
containing both MFGM lipids and MFGM proteins was
reported to minimise age-associated loss of muscle mass
and force-generating capacity in senescence-accelerated
mice (SAMP1 mice) [40]. Furthermore, several recent
human clinical trials have reported apparent potential
beneficial effects of dietary MFGM supplementation on
neuromuscular function when combined with exercise
training [41–43]. However, whether dietary supplementa-
tion with MFGM mixtures has direct effects on skeletal
muscle plasticity, the specific MFGM components that
exert bioactivity and the underlying mechanisms involved
remains unclear.
In the present study, we examined the effect of dietary
supplementation with bovine-derived MFGM mixtures,
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differing in the composition of PLs/sphingolipids and
presence of MFGM proteins, during post-natal develop-
ment on neuromuscular plasticity in growing rats. Spe-
cifically, we analysed the effect of feeding MFGM during
development on the resulting adult muscle phenotype
and the expression of the myogenic, synaptogenic and




Experiments were approved by the Animal Ethics Commit-
tee, The University of Auckland (001260). Eight independ-
ent litters of Wistar rats were received from the animal
resource unit of the University of Auckland at post-natal
(PN) day 7. The litter size was normalised at birth to eight
male pups per litter. At PN day 10, the pups were ran-
domly allocated to receive dietary supplementation with
blank gelatin (BG) or gelatin cubes formulated with one of
three different bovine-derived MFGM mixtures (details
below) (supplied by Fonterra Co-operative Group Limited).
The pups were weaned at PN day 21 and experiments were
terminated at PN day 70.
MFGM formulation and dietary supplementation
Gelatin cubes were used for administration of the dietary
supplements, which were formulated using raspberry fla-
vouring and gelatin (10% w/v) containing sucrose (10% w/
v) as previously described [32, 33, 36, 44]. Briefly, the
MFGM mixtures were dissolved in water using a food pro-
cessor and were then mixed with 1 L of gelatin/sucrose
mixture at 50 °C. The mixture was then transferred into ice
cube trays and was firmed at 4 °C. Each cube contained
12.5 mL of gelatin/sucrose solution, with or without an
added MFGM mixture. Three different MFGM mixtures
were tested; they were administered at various absolute
doses so as to match the administered amount of ganglio-
sides (GD3), an established brain bioactive molecule [35].
The bovine-derived MFGM supplements tested included a
complex milk lipid (CML) mixture (reported previously in
[33, 35, 44]), beta serum concentrate (BSC) (reported previ-
ously in 32) and a polar-lipid-enriched complex milk lipid
concentrate (CMLc, “PGC80”) that lacks an MFGM pro-
tein component (reported previously in 36). The dose of
CML used and the standardised ganglioside concentration
were based on our previously published study in which de-
veloping rats received dietary supplementation with CML
containing 5.9% gangliosides, at a dose of 1% w/w of dietary
intake [35]. The gross compositions of the three different
MFGM mixtures are described in Table 1.
A total of 64 animals (eight pups from eight independent
litters) were studied (n = 16 per group). Treatment was
performed within litter, to minimise the effect of between-
litter variability. On PN day 10, two pups within each litter
of eight were randomly allocated into one of the four treat-
ment groups. The rats were hand fed from PN day 10 until
PN day 21 (weaning day) and were individually cage fed
thereafter until PN day 69 (week 10). The dose of MFGM
supplementation was calculated daily based on animal
body weight. The doses of CML, BSC and CMLc were
0.64, 5.05 and 1.78 mg/g/day respectively. The control
group was fed with BG cubes, which were prepared identi-
cally except without the addition of any MFGM mixture.
The rats were single caged with the allocated gel treatment
for 1–2 h each day and were returned to their home cage
after they had consumed the gels.
Tissue collections
On PN day 70, the rats were deeply anaesthetised
with pentobarbital (125 mg/kg, i.p.) and blood sam-
ples (1–2 mL) were collected via cardiac punctures
using heparin as an anticoagulant. Blood plasma was
separated by centrifugation prior to storage at −80 °C.
The rats were transcardially perfused with normal sa-
line until the outflow from the heart ran clear. The
posterior musculature of the lower left hind limb (tri-
ceps surae) was dissected and the soleus muscle was
removed intact. The soleus muscle was weighed and
then cut in half transversely at the mid belly. One
portion of the soleus was snap frozen in liquid nitro-
gen and stored at −80 °C for molecular analysis. The
remaining half was covered in Cryoglue optimum cut-
ting temperature (OCT) compound (SLEE medical,
Mainz, Germany) and rapidly frozen in dry-ice-cooled
isopentane for subsequent immunohistological analysis.
Table 1 Compositions of the supplements (g/100 g)
CML BSC CMLc
Protein 7.0 52.3 0.0
MFGM protein present N Y N
MFGM structure present N Y N
Total fat 80.0 36.2 88.0
PLs 45.2 13.7 71.7
PC (% total PLs) 14.5 27.0 23.1
PE (% total PLs) 27.2 29.2 34.7
PI (% total PLs) 18.7 8.8 8.8
PS (% total PLs) 26.1 12.1 12.0
Ganglioside GD3 4.8 0.63 1.8
PL:GD3 ratio 9.4 21.7 39.8
Lactose 3.0 6.6 3.2
Minerals 8.0 5.2 9.1






CML complex milk lipids, BSC beta serum concentrate, CMLc complex milk lipid
concentrate, MFGM milk fat globule membrane, PL phospholipid, PC
phosphatidylcholine, PE phosphatidylethanolamine, PI phosphatidylinositol, PS
phosphatidylserine, SM sphingomyelin
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Immunohistochemical analysis of muscle tissue
Cross-sections (10 μm) were cut from the mid belly of
OCT-embedded soleus muscles in a cryostat at −20 °C
(Leica CM3050 S, Leica Biosystems, Nussloch, Germany).
Tissue sections were adhered to SuperfrostTM Plus slides
(Thermo Fisher Scientific, Waltham, MA, USA) and were
air-dried at room temperature. The slides were blocked in
10% goat serum (GS; Vector Laboratories, Burlingame,
CA, USA) in phosphate buffered saline (PBS) at room
temperature for 2 h, prior to overnight incubation with a
cocktail of immunoglobulin (Ig) sub-class specific mouse
monoclonal primary antibodies against MyHCI (BA-F8,
mouse IgG2b, diluted 1:12.5), MyHCIIa (SC-71, mouse
IgG1, 1:600) and MyHCIIb (BF-F3, mouse IgM, 1:25) as
previously described [45]. An antibody against laminin
(2E8, mouse IgG2a, 1:50) was used simultaneously to stain
the basal lamina surrounding each myofibre. Monoclonal
antibodies were obtained from the Developmental Studies
Hybridoma Bank, created by the NICHD of the NIH and
maintained at The University of Iowa, Department of Biol-
ogy, Iowa City, IA, USA. This method allows for visualisa-
tion of all four rodent MyHC isoforms simultaneously,
together with the muscle fibre boundaries, on a single
tissue section because MyHCIIx fibres remained un-
stained [45]. All primary antibodies were prepared in 10%
GS solution in PBS. Following overnight primary antibody
incubation, the slides were washed five times, for 5 min
each time, in PBS prior to incubation with Alexa Fluor
goat anti-mouse secondary antibodies (Alexa Fluor 350
IgG2b, Alexa Fluor 488 IgG1, Alexa Fluor 555 IgM and
Alexa Fluor 647 IgG2a; Life Technologies, Carlsbad, CA,
USA) for 2 h at room temperature. All secondary anti-
bodies were diluted 1:500 in PBS. Following five further
washes, for 5 min each time, in PBS, the slides were
mounted with coverslips in Immu-Mount aqueous
mounting medium (Thermo Fisher Scientific, Waltham,
MA, USA). Antibody staining was visualised and images
were captured at 10× magnification using an upright
fluorescence microscope (Axio Imager Z2, Carl Zeiss,
Oberkochen, Germany) equipped with a fully motorised
automatic stage (VSlide Scanner, MetaSystems, Alltlus-
sheim, Germany). Sequential images, spanning the entire
area of the muscle cross-section, were captured and were
then tiled into a single composite image using V-slide soft-
ware. Global linear adjustments to the image fluorescent
signal brightness and contrast were made in MetaViewer
software (MetaSystems Alltlussheim, Germany). Semi-
automated quantitative analysis was performed using
Image J software to determine the muscle fibre type and
the cross-sectional area (CSA) of individual myofibres. All
fibres within the muscle section were analysed. Whilst the
IHC staining method used potentially allows for the iden-
tification of hybrid myofibres the image analysis procedure
used includes all fibres which express MyHCIIa myosin
(including hybrid MyHCI/MyHCIIa) as Type IIa fibres.
Thus, whilst the quantification procedure used does not
specifically allow for analysis of the specific contribution
of hybrids, any hybrid fibres present would contribute to
the total MyHCIIa + fibre count.
RNA Extraction and Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted from a ~ 20 mg piece of frozen
soleus muscle using the RNeasy kit (Qiagen, Venlo,
Netherlands) as per the manufacturer’s instructions. The
RNA concentration was determined using a NanoDrop
1000 spectrophotometer. The RNA samples were diluted
in nuclease-free water and first-strand cDNA synthesised
from 0.5 μg of total RNA using the High-Capacity cDNA
Reverse Transcription Kit (Life Technologies, Carlsbad,
CA, USA). RT-PCR was performed on a LightCycler 480
using LightCycler 480 SYBR Green I Master mix (Roche
Applied Science, Indianapolis, IN, USA). The RT-PCR
fluorescent emission data were analysed for the cycle
threshold (Ct) value. Gapdh was selected as an appropri-
ate housekeeping gene and was used for normalisation
and quantification of the target mRNA PCR data by the
2(−ΔCt) method. A standard curve and a melting curve
were performed for each primer pair to confirm efficiency
and single product amplification. Primer sequences used
are presented in Additional file 1: Table S1.
HPLC–MS Analysis of Plasma and Tissue PLs
Rat muscle samples (~50 mg) were homogenised in
1 mL of Milli Q water using 2.8 mm ceramic beads in a
OMNI Bead Ruptor Homogeniser (Omni International,
Kennesaw, GA, USA) (5.65 m/s, 2 × 1 min). Lipids were
extracted from the rat muscle homogenate and plasma
samples (0.25 mL) using the modified Svennerholm and
Fredman [46] extraction protocol as described by Norris
et al. [47]. The final non-polar chloroform fraction con-
taining the PLs was made to 5 mL in choloroform/
methanol (2:1) and used for PL analysis. The analysis of
PLs was performed on an ACQUITY UPLC system
(Waters, Milford, MA, USA), equipped with an APS-2
Hypersil column (150 mm × 2.1 mm, 3 μm, Thermo
Electron Corporation, Waltham, MA, USA), and inter-
faced to a TSQ Quantum mass spectrometer (Thermo
Electron Corporation, Waltham, MA, USA) using a
heated electrospray ionisation source as previously de-
scribed [44]. The PLs were detected using precursor
ion or neutral losses that occur to the PLs during
fragmentation [48].
Data analysis
The data were assessed for normality using the Shapiro–
Wilk test. Variables that were found not to be normally
distributed were transformed (log or square root) in
Markworth et al. Nutrition & Metabolism  (2017) 14:9 Page 4 of 14
order to achieve the assumption of normality. Data
between the four supplementation groups were com-
pared using a one-way analysis of variance (ANOVA).
Following a significant main ANOVA effect, Holm-Šidák
post-hoc tests were performed to compare each of the
experimental groups with the control (BG) group. The
PL compositions of plasma and muscle tissue were ana-
lysed by two-way ANOVA with supplementation group
and PL species class as factors. The data are presented
as means ± SEM. p < 0.05 was considered to be statisti-
cally significant.
Results
Body and muscle weights
There was no significant effect of MFGM mixture supple-
mentation group on animal body weight, soleus muscle
weight or soleus weight when normalised to body weight
(mg/g body weight).
Plasma and muscle PL composition
The plasma PL concentration showed a significant inter-
action effect (p < 0.001) between the MFGM supplemen-
tation group and the type of PL species (Fig. 1a). PC was
by far the most abundant PL species detected in plasma
and was present at significantly higher concentrations
compared with the other PL species (Fig. 1a). The
plasma PC concentration was futher increased above
that in the BG group in both the BSC group (p < 0.01)
and the CMLc group (p < 0.001) but not the CML group
(Fig. 1a). The plasma concentrations of other PLs, in-
cluding PI, PE and SM, were not significantly influenced
by the MFGM supplementation group (Fig. 1a). How-
ever, plasma lyso-phosphatidylcholine (L-PC) was found
to be elevated in the CML group (p < 0.05) but not in
the BSC and CMLc groups (Fig. 1a). Analysis of the PL
composition of skeletal muscle tissue samples showed
main effects of supplementation group (p < 0.01) and PL
species (p < 0.001) (Fig. 1b). Similar to plasma, PC was
the predominant PL species that was detected in muscle,
although, unlike in plasma, PE was also found to be a
major component within the muscle tissue homgenates
(Fig. 1b). Compared with the BG group, the intramuscu-
lar concentration (μg/mg) of PC was significantly lower
in the BSC group (p < 0.01) and the CMLc group (p
< 0.01) (Fig. 1b). In contrast, no effect of CML sup-
plementation on the muscle PC concentration was
apparent. The muscle concentrations of PI, PE, PS
and SM were not influenced by dietary supplementa-
tion with any of the three MFGM mixtures (Fig. 1b).
Muscle fibre type composition
There was a significant effect of supplementation group
on the absolute number of MyHCIIa-positive myofibres
within the soleus muscle (p < 0.05) (Fig. 2b). Similarly,
there was a significant effect of supplementation group
on the MyHCIIa fibre number expressed as the percent-
age of total fibres analysed (% composition of MyHCIIa-
positive fibres) (p < 0.05) (Fig. 2c). Post-hoc analysis
revealed an increase in both the absolute number
(Fig. 2b) and the % composition (Fig. 2c) of MyHCIIa fi-
bres in rats supplemented with the BSC and CMLc
MFGM mixtures. In contrast, there was no significant
effect of the CML MFGM mixture on the muscle fibre
type composition. These data indicate a “slow-to-fast”
fibre type shift from Type I (MyHCI-positive) towards
Type IIa (MyHCIIa-positive) muscle fibres in the soleus
muscle of rats receiving supplementation with the BSC
and CMLc MFGM mixtures but not the CML MFGM
mixture.
Muscle fibre size
There was no significant effect of supplementation with
any of the three MFGM mixtures on the CSA of Type I
(MyHCI-positive) (Fig. 3b) or Type IIA (MyHCIIa-positive)
myofibres (Fig. 3c). These data suggest that supplementa-
tion with MFGM components did not alter the soleus
muscle fibre size.
Fig. 1 Muscle and plasma phospholipid (PL) concentrations in rats
receiving dietary supplementation with various milk fat globule
membrane (MFGM) mixtures. a Plasma concentration (mg/mL) of PL
species. b Muscle concentration (μg/mg wet weight) of PL species
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Skeletal muscle mrna expression
Contractile protein genes
As expected, mRNA expression of genes encoding the
slow-twitch MyHCI (Myh7) and intermediate-fast MyH-
CIIa (Myh2) isoforms was abundant in the predomin-
antly tetanic slow-twitch soleus muscle. Expression of
mRNA encoding the fast-twitch rodent myosin isoforms
MyHCIIx (Myh1) and MyHCIIb (Myh4) was low and
highly variable in this muscle (Fig. 4a). There were sig-
nificant between-group differences in mRNA expression
of Myh2 in the soleus by one-way ANOVA (p < 0.05).
Post-hoc analysis showed that Myh2 expression was
increased in the CMLc group compared with the BG
group (p < 0.05). A similar trend towards elevated ex-
pression of Myh2 was observed for the BSC group, but
this failed to achieve statistical significance (p = 0.08 vs
BG). Supplementation with the CML MFGM mixture
had no effect on Myh2 mRNA expression. There was no
effect of any of the three MFGM mixtures on mRNA
expression of the slow-twitch MyHCI isoform (Myh7),
nor on the expression of troponin I type 1 (skeletal,
slow) (Tnni) or troponin I type 2 (skeletal, fast) (Tnni2)
(Fig. 4a).
Myogenic regulatory factors
To further explore the mechanisms by which MFGM
supplementation may influence the skeletal muscle
phenotype, we measured the expression of the myogenic
regulatory factor (MRF) genes that are involved in skel-
etal muscle development and satellite cell myogenesis in
mature muscle tissue (Fig. 4b). There were significant
between-group differences by one-way ANOVA for
muscle mRNA expression of all four MRF family mem-
bers including Myf5 (p < 0.05), Myod1 (p < 0.05), Myog
(p < 0.001) and Myf6 (p < 0.05) (Fig. 4b). Post-hoc tests
revealed that Myog mRNA levels were higher in the
CML (p < 0.001), BSC (p < 0.001) and CMLc (p < 0.001)
groups compared with the BG group. However, ex-
pression of Myf5 (p < 0.01), Myod1 (p < 0.05) and Myf6
(p = 0.05) was significantly increased only in the BSC
Fig. 2 Muscle fibre type composition of the soleus muscle of rats supplemented with various milk fat globule membrane (MFGM) mixtures during
post-natal development. a Representative images of soleus muscle cross-sections probed with mouse monoclonal antibodies against MyHCI (IgG2b,
Alexa Fluor 350, blue), MyHCIIa (IgG1, Alexa Fluor 488, green), MyHCIIb (IgM, Alexa Fluor 555, red) and laminin (IgG2a, Alexa Fluor 647, far-red, pseudo
coloured red). b Total number of soleus muscle fibres staining positive for MyHCIIa. c Percentage composition of total myofibres staining positive for
MyHCIIa. * p < 0.05 vs BG group
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group. Similar trends towards elevated expression of
Myf5 (p = 0.06 vs BG) and Myf6 (p = 0.16 vs BG) were
observed in the CMLc group, but these failed to reach
statistical significance.
Fibre type specialisation genes
Compared with the BG group, mRNA expression of
Nfatc4 was elevated in both the BSC group (p < 0.001)
and the CMLc group (p < 0.01) (but not the CML group)
(Fig. 4c). No difference between groups was observed for
mRNA expression of the other NFAT isoforms, includ-
ing Nfatc1, Nfatc2 and Nfatc3.
Neuromuscular gene expression
Synaptogenic genes
mRNA expression of components of the agrin–LRP4–
MuSK signalling pathway, including Agrn (p < 0.001),
Lrp4 (p < 0.05), Musk (p < 0.001) and Rapsn (p < 0.05),
were found to be significantly different between the sup-
plementation groups by one-way ANOVA (Fig. 5A).
Post-hoc analysis showed that dietary supplementation
with both BSC and CMLc increased the expression of
Agrn (both p < 0.01), Lrp4 (the Agrn receptor) (both
p < 0.05) and Musk (CMLc p < 0.001, BSC p < 0.05).
However, only the CMLc group displayed elevated
muscle expression of Rapsn. Unlike supplementation
with BSC and CMLc, supplementation with the CML
mixture had no significant effect on the expression
of LRP4–MuSK signalling pathway components.
Pre-synaptic components
The Agrn primer pair used above (Agrn 1 F: TTCCTC
AGCAACTACAAACCTG, Agrn 3R: TTCACACACAG-
CACCAAAGC) amplify a region of rat Agrn mRNA
spanning exons 1 to 3 ubiquitous to all Agrn splice vari-
ants (both muscle Z- and nerve Z+ isoforms). In order
Fig. 3 Soleus muscle myofibre cross-sectional area (CSA) (μm2) in rats supplemented with various milk fat globule membrane (MFGM) mixtures.
a Representative images of soleus muscle cross-sections probed with mouse monoclonal antibodies against MyHCI (IgG2b, Alexa Fluor 350, blue),
MyHCIIa (IgG1, Alexa Fluor 488, green), MyHCIIb (IgM, Alexa Fluor 555, red) and laminin (IgG2a, Alexa Fluor 647, far-red, pseudo coloured red).
b Mean CSA (μm2) of soleus muscle Type I (MyHCI-positive) myofibres. c Mean CSA (μm2) of soleus muscle Type IIa (MyHCIIa-positive) myofibres
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to determine whether mRNA of the nerve derived Z+
Agrn isoforms mRNA (which possess substantially
greater AChR cluster aggregation bioactivity) could be
detected within whole skeletal muscle samples, and
whether apparent differences in Agrn expression were
exclusively attributable to modulation of Z− Agrn iso-
forms known to be expressed by myofibres themselves,
we designed primers to specifically amplify agrin mRNA
splice variants that include exon 32 (corresponding to
protein isoforms Z8 and Z19) [49]. RT-PCR reactions
with a forward primer specific for exon 30 (Agrn 30 F:
TGTCCTGGGGGCTTCTCTGG) in combination with
a reverse located within exon 32 (Agrn 32R: CTGG
GATCTCATTGGTCAGCTC) present only in the nerve
derived Z + 8 (containing exon 32 but lacking exon 33)
and Z + 19 (containing both exons 32 and 33) splice var-
iants demonstrated amplification of rat muscle tissue
cDNA samples not observed in RT− or non-template
control samples (Fig. 5b, Additional file 2: Figure S1).
Agarose gel (4%) electrophoresis of the amplified RT-
PCR products revealed bands corresponding to the
expected sizes of 102 bp with the Agrn 1 F/Agrn 3R (pan
Agrn) primer pair and 149 bp with Agrn 30 F/Agrn 32R
(Z+ Agrn) primer pair. Sequencing of these bands fol-
lowing gel extraction/purification confirmed that the
102 bp product generated with Agrn 1 F/Agrn 3R
primers aligned with a region of rat Agrn between exons
1–3 and the 149 bp product with Agrn 30 F/Agrn 32R
aligned with region located within alternatively spliced
exon 32 (CGAGCTGACCAATGAGATCCCAG) present
only in the nerve derived Z+ isoforms (Additional file 2:
Figure S1). Real time RT-PCR reactions with the Agrn
30 F/Agrn 32R primer pair showed that the expression
of Z+ Agrn mRNA within muscle tissue significantly dif-
fered between supplementation groups by one-way
ANOVA (p < 0.05) (Fig. 5b). Post-hoc analysis demon-
strated significantly elevated muscle Z+ Agrn mRNA
expression in the CMLc group when compared to the
BG group. Neither CML nor BSC supplementation
had any significant effect on the expression of Z+
Agrn (Fig. 5b).
Consistent with our observation of detectable expres-
sion of nerve derived Z+ Agrn mRNA in whole muscle tis-
sue; mRNA of the synaptic vesicle protein synaptophysin
(Syp) was also apparently detected. Agarose gel (4%) elec-
trophoresis of the amplified product from the real time
PCR reactions (Syp F: TTTGCTACGTGTGGCAGCTA,
Syp R: ACACTTGGTGCAGCCTGAAG) showed a band
corresponding to the expected size of 121 bp. Sequencing
of the 121 bp band following gel extraction/purification
confirmed that the amplified product aligned with rat Syp
mRNA (Additional file 2: Figure S2). Real time RT-PCR
reactions with the Syp F/Syp R primer pair revealed that
muscle Syp expression was significantly different between
groups by one-way ANOVA (p < 0.05) with post-hoc
analysis showing significantly elevated Syp in BSC supple-
mented animals. Finally, soleus mRNA expression of
neural cell adhesion molecule (Ncam1) was also signifi-
cantly different between groups (p < 0.01). Ncam1 was
elevated in the BSC (p < 0.05) and CMLc (p < 0.05)
groups compared with the BG group (Fig. 5a). In
Fig. 4 Dietary supplementation with lipid-enriched milk fat globule
membrane (MFGM) mixtures influences muscle gene expression.
a mRNA expression of transcripts encoding muscle contractile proteins
in the soleus of rats receiving dietary supplementation with blank gel
(BG), complex milk lipids (CML), beta serum concentrate (BSC) or
complex milk lipd concentrate (CMLc). b mRNA expression of
myogenic regulatory factor (MRF) genes in the soleus muscle of
rats receiving dietary supplementation with BG, CML, BSC or
CMLc. c mRNA expression of NFAT isoforms in the soleus muscle
of rats receiving dietary supplementation with BG, CML, BSC or
CMLc. Values are mean ± SEM. * p < 0.05 vs BG group
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contrast, Ncam1 expression did not differ between
the CML and BG groups.
Post-synaptic neuromuscular components
mRNA expression of AChR subunits alpha 1 (Chrna1)
(p < 0.01), beta (Chrnb1) (p < 0.05) and gamma (Chrng)
(p < 0.01) was significantly different between the supple-
mentation groups (Fig. 5c). AChR delta (Chrnd) also
showed a similar trend towards between-group differ-
ences, but this failed to reach statistical significance
(p = 0.09). Post-hoc analysis revealed that Chrng
mRNA was elevated in both the BSC and CMLc
groups when compared with the BG group. Expres-
sion of Chrna1 was also elevated only in the BSC
group, although the CMLc group exhibited a similar
trend (p = 0.08 vs BG). Only the CMLc group exhib-
ited significantly increased muscle mRNA expression
of Chrnb1. Expression of the AChR epsilon subunit
(Chrne) did not differ between the MFGM supple-
mentation groups.
Discussion
The current study assessed the effect of dietary supple-
mentation with different bovine-derived MFGM mixtures
on post-natal neuromuscular development in growing
rats. None of the MFGM supplements tested here had any
effect on soleus muscle mass or myofibre size. However, a
slow-to-fast shift, i.e. Type I towards Type IIa muscle
fibres was observed in rats supplemented with both BSC
and CMLc, which occurred as a result of an increase in
both the absolute number and the relative concentration
of Type IIa fibres. The effect of BSC and CMLc supple-
mentation on muscle phenotype was associated with ele-
vated expression of genes involved in myogenesis (MRFs),
fibre type specialisation (Myh2 and NFATc4) and neuro-
muscular plasticity/synaptogenesis (agrin–LRP4 pathway).
These findings show that dietary supplementation with
bovine-derived MFGM mixtures that are enriched in polar
lipids promotes neuromuscular development in rats.
Skeletal muscles are still immature at birth and im-
portant changes in the muscle fibre type profile, which
coincide with maturation of the neuromuscular system,
take place during early post-natal development, includ-
ing the disappearance of polyneuronal innervation and
the acquisition of specific motor neuron firing patterns
[2]. The development and the maintenance of the fibre
type profile of tetanic slow-twitch muscles (e.g. the
soleus) are particularly dependent on nerve activity.
In the current study, rats that received dietary supple-
mentation with BSC and CMLc (but not CML) displayed
a greater proportion of muscle fibres staining positive for
the MyHCIIa isoform within the soleus muscle at PN day
70. RT-PCR analysis of muscle gene expression suggested
that this effect appeared to be primarily attributable to
Fig. 5 Milk fat globule membrane (MFGM) supplementation influences
neuromuscular gene expression. a mRNA expression of components of
the agrin–LRP4 pathway in the soleus muscle of rats receiving dietary
supplementation with BG, CML, BSC or CMLc. b mRNA expression of
nerve cell markers in the soleus muscle of rats receiving dietary
supplementation with blank gel (BG), complex milk lipids (CML), beta
serum concentrate (BSC) or complex milk lipid concentrate (CMLc).
c mRNA expression of acetylcholine receptor (AChR) subunits in the
soleus muscle of rats receiving dietary supplementation with BG, CML,
BSC or CMLc. Values are mean ± SEM. * p < 0.05 vs BG group
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elevated expression of the intermediate-fast MyHCIIa
isoform (Myh2 gene), with no indication of suppressed
expression of the slow-twitch MyHCI isoform (Myh7
gene). We also measured expression of the skeletal muscle
contractile protein isoforms slow troponin (Tnni1) and
fast troponin (Tnni2), but found that they were not influ-
enced by MFGM supplementation. These data suggest
that dietary supplementation with specific MFGM mix-
tures during post-natal development leads to shifts in the
adult muscle fibre type profile that are primarily attribut-
able to upregulation of the intermediate-fast Type IIa
myosin isoform. An increase in the percentage of Type IIa
myofibres within the soleus muscle would potentially be
expected to lead to changes in muscle function including
an increased force generating potential. Although no mea-
sures of muscle function were undertaken in the current
study, our soleus muscle fibre type composition results
may explain the previously reported positive effect of
MFGM on tetanic contractile force of the soleus muscle
in mice [40]. The soleus muscle is a prototypical slow-
twitch muscle consisting primarily of Type I myofibres
and thus a slow-to-fast fibre type shift could be seen to
disrupt the normal profile of the soleus with the potential
for possible negative effects on oxidative capacity. Never-
theless, Satoshi et al. 2014 reported that mice receiving
MFGM supplementation displayed increased muscular
endurance capacity in association with increased soleus
muscle mRNA expression of oxidative genes including
peroxisome proliferator-activated receptor-γ coactivator
1α (Pgc1α) and Cpt-1b [50].
Previous studies that have investigated the effect of nu-
trition on skeletal muscle fibre type have utilised models of
energy surplus or deficit including high-fat-diet-induced
obesity and caloric restriction [8]. In response to short
term feeding of rodents with a high fat diet, a number of
studies have reported a fast-to-slow fibre type profile shift
in skeletal muscle [51–55], associated with a concurrent in-
crease in muscle oxidative capacity [56–58]. In contrast, a
single recent study reported slow-to-fast muscle fibre type
transformation in response to a more prolonged (1 year)
high fat diet in mice [59]. In the present study, we observed
an increase in the absolute number and the relative pro-
portion of Type IIa myofibres in the soleus muscle of rats
fed BSC and CMLc, despite very little difference in overall
caloric intake and macronutrient composition of the four
diets. This suggests that supplementation with specific
MFGM mixtures enriched in polar lipids exerted bioactive
effects on the muscle fibre type profile independent of cal-
oric/nutritional value. MFGM contains numerous poten-
tially bioactive molecules including polar lipids as well as
specific membrane proteins [21–23]. As all three tested
MFGM supplements were matched for ganglioside content
in the present study (and yet CML was without effect), it
appears to be unlikely that the effects observed are related
to the dietary intake of gangliosides. Furthermore, BSC is a
complex mixture of ingredients, including a substantial
MFGM protein component, which is lacking in the more
purified CMLc mixture. Despite this, overall, the effects of
BSC and CMLc were very similar. Thus, overall, the effects
observed here also do not appear to be primarily attribut-
able to a bioactive MFGM protein component. Although
further investigation into the bioactive composites is re-
quired, collectively, these lines of evidence suggest that the
polar lipid composition of bovine MFGM is a likely soure
of bioactivity.
Phospholipids and sphingolipids have established bio-
active properties related to neuroplasticity as well as muscle
cell growth and development [37–39]. For example, cell
surface exposure of PS on myoblasts is an indispensable
event for myoblast fusion [60, 61] and treatment with PS li-
posomes can enhance muscle fibre formation in vitro [62].
Conversely, ablation of the PS receptor has been found to
impair muscle regeneration following injury in mice
[63, 64]. SM levels also relate to the state of activation
of muscle myogenic precursor cells (satellite cells) [65],
with SM metabolism to the metabolite sphingosine-1-
phosphate (S1P) being a crucial pathway in satellite cell
activation/proliferation [66–70], myoblast migration
[71] and myogenic differentiation [72–77]. Further-
more, in vivo treatment with S1P has been shown to
protect against contraction-induced muscle fatigue
[78], minimise denervation-induced muscle atrophy
[79] and enhance skeletal muscle regenerative capacity
following traumatic injury [80]/damaging muscle con-
tractions (exercise) [81]. Consistent with a positive role
of polar lipids in the regulation of muscle cell growth
and development, in the current study, we found that
dietary supplementation with PL-enriched MFGM mix-
tures increased muscle expression of the MRFs includ-
ing Myf5, Myod1, Myog and Mrf4. The MRFs play a
crucial role in embryonic myogenesis, but also play
multiple distinct roles in post-natal muscle, including
developmental growth, fibre type control and growth/
regeneration of adult myofibres in response to injury
caused by mechanical loading. For example, Myod1 is
expressed more highly in fast-twitch fibres than in
slow-twitch fibres and Myod1-null mice show shifts in
fibre type of fast muscle towards a slower phenotype
[82, 83]. Conversely, overexpression of an active form
of Myod1 in muscle results in a slow-to-fast fibre type
conversion [84].
Nuclear factor of activated T cell (NFAT) family mem-
bers are known to play a major role in converting fast
and slow motor neuron stimulation patterns into specific
transcriptional programs that drive muscle fibre type
specialisation [85, 86].We detected expression Nfatc1,
Nfatc2, Nfatc3 and Nfatc4 mRNA in adult soleus
muscle, but found that only Nfatc4 was induced in
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response to MFGM (BSC and CMLc) supplementation.
An indispensable role of Nfatc1 in the maintenance of a
slow muscle phenotype is well established [86, 87]. How-
ever, more recent work has shown that, depending on
the applied nerve activity pattern, different combinations
of NFAT isoform expression contributes to the transcrip-
tion of muscle fibre type specific genes [85]. For example,
transcription of MyHC genes in the predominantly fast-
twitch rat extensor digitorum longus (EDL) muscle uses
different combinations of NFAT isoforms, ranging from
MyHC-slow, which uses all four NFAT isoforms, to MyH-
CIIb, which requires only Nfatc4 [85]. The precise role of
Nfatc4 in fibre type specialisation of the predominantly
slow-twitch soleus muscle, which generally lacks expres-
sion of the MyHCIIb isoform, is unclear. Nevertheless, the
notion that Nfatc4 is specifically involved in driving the
expression MyHC isoforms associated with a relatively
faster muscle phenotype [85] is consistent with the Type 1
to Type IIa soleus muscle fibre type shift, concurrent to
elevated Nfatc4 expression, that was observed in response
to MFGM supplementation in the current study.
Multiple splice variants of agrin exist which vary
via the inclusion or exclusion of exons 32 and/or 33
(nomenclature of ref 14). Whereas most cell types
synthesize agrin, only neurons produce the alterna-
tively spliced Z+ agrin isoforms that include the
sequence encoded by exons 32 and/or 33 [12]. These
Z+ exons encode a domain of 8–19 amino acids that
confers up to a 1,000-fold increase in AChR cluster-
ing activity relative to Z- agrin [14]. Additionally, the
Z8 (with 8 additional amino acids encoded by exon
32) and Z19 (with 19 amino acids encoded by exons
32 and 33) isoforms are 150-fold more potent in pro-
moting AChR clustering than isoforms lacking exon
32 and 45-fold more potent than the Z11 isoform
(including exon 33 alone) [88–90]. Using a primer
pair spanning exons 1–3 of rat Agrn mRNA (which is
present in all splice variants) we found that Agrn
mRNA expression was increased in the muscle of rats
receiving dietary supplementation with BSC or CMLc,
but not CML. Since Z- agrin variants have previously
been found to be the only isoforms expressed within
skeletal muscle tissue [12], this finding likely reflects
an effect of MFGM supplementation on muscle de-
rived agrin. However, using primers designed to spe-
cifically amplify Agrn mRNA splice variants that
include exon 32 (corresponding to protein isoforms
Z8 and Z19) we were apparently also able to detect
expression of the Z+ Agrn mRNA within the rat so-
leus muscle. Gel electrophoresis confirmed a band of
the expected size which aligned with the region
within spliced exon 32 following band extraction and
sequencing. On the basis of previous reports [12], we
can only presume that Z+ Agrn mRNA expression
detected was derived from motor neuron axons and/
or presynaptic motor nerve terminals located within
the muscle tissue. Rats receiving CMLc supplementation
appeared to display significantly increased expression of Z+
Agrn when compared to BG, suggesting increased Agrn ex-
pression in CMLc supplemented animals may be at least
partially due to induction nerve Agrn. Consistent with this
hypothesis was detection and modulation of mRNA ex-
pression of the pre-synaptic nerve terminal marker synap-
tophysin within rat muscle. Increased muscle Agrn and
neural Z+ Agrn mRNA expression in the soleus muscle tis-
sue of MFGM supplemented rats was also accompanied by
elevated muscle expression of downstream components of
the post-synaptic agrin–LRP4 signalling pathway, including
the agrin receptor Lrp4, the associated receptor tyrosine
kinase Musk and the intracellular AChR-clustering protein
Rapsn. The role of agrin in the determination of muscle
phenotype has been investigated recently in mice in which
the levels of agrin at the NMJ were reduced by overexpres-
sion of neurotrypsin enzyme, which cleaves active agrin to
form inactive CAFs (SARCO mice) [19]. Young adult
SARCO mice exhibit a precocious sarcopenic phenotype
that is characterised by loss of muscle force, destabilisation
of NMJs and a preferential loss of fast-twitch type II myofi-
bres [19]. Consistently, loss of agrin function as the result
of a point mutation results in deterioration of the NMJ,
leads to muscle fibre atrophy and leads to a fast-to-slow
muscle fibre type shift [91]. Plasma CAFs have been found
to be elevated in elderly humans, suggesting that they may
be a useful biomarker of sarcopenia arising from age-
associated neuromuscular decline [15–18]. Interestingly, in-
jection of an agrin biologic (NT-1654) was able to reverse
the sarcopenia-like phenotype in SARCO mice, suggesting
that modulating the agrin–LRP4–MuSK pathway may be a
novel therapeutic strategy in the treatment of age-related
muscle wasting, neuromuscular disease and associated
muscle dysfunction [20]. To our knowledge, the present
study is the first report of the modulation of muscle agrin
levels as a result of nutritional supplementation. These
findings suggest that dietary ingestion of, or dietary supple-
mentation with, bovine MFGM or composite material
could be a potential therapeutic means of manipulating the
agrin–LRP4 pathway in muscle tissue.
Previously, Haramizu et al. reported the effect of dietary
supplementation with an MFGM mixture in combination
with habitual exercise in age related muscle dysfunction
using a model of senescence-accelerated mice (SAMP1
mice) [40]. SAMP1 mice that received combined MFGM
and exercise exhibited increased muscle mass (quadriceps)
and contractile force (soleus and EDL) [40]. Interestingly,
microarray analysis of the quadriceps muscle revealed that
transcripts related to the biological process of “nervous
system development and function” were most differen-
tially expressed between the MFGMEx group and the
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control SAMP1 group [40]. Subsequent verification by
PCR analysis showed significant induction of the neuro-
muscular/synaptogenic genes Musk and Dok7, as well as
the myogenic genes Myod1 andMyog, in response to com-
bined MFGM supplementation and habitual exercise [40].
However, no significant differences were found in re-
sponse to MFGM supplementation when administered in
the absence of habitual exercise [40]. In support of the
findings of Haramizu et al. [40], we report induction of
several of the same genes (Myod1, Myog, Musk) or closely
related genes (e.g. other MRFs and agrin–LRP4 pathway
components) in muscle tissue of rats supplemented with
BSC and CMLc, even in the absence of an exercise stimu-
lus. To our knowledge, the current study is the first report
of a direct effect of MFGM supplementation on the ex-
pression of genes related to nervous system development
independent of an exercise stimulus. As early post-natal
life is a stage of neuromuscular plasticity, direct effects of
dietary MFGM supplementation on skeletal muscle tissue
may be more readily observed in this model. However, in
adult skeletal muscle, it is possible that a remodelling
stimulus (e.g. exercise) may be necessary for MFGM
supplementation to exert a modulatory bioactive effect.
Conclusion
In conclusion, we found that dietary supplementation with
specific bovine-derived MFGM mixtures, including BSC
and CMLc, which are enriched in polar lipid components,
promotes neuromuscular development in growing rats,
leading to shifts in the adult’s muscle phenotype. These
findings suggest that previously reported effects of MFGM
or composite molecules on neuroplasticity may extend be-
yond the central nervous system and may impact periph-
eral tissues including skeletal muscle. On the basis of these
findings, ingestion of dietary sources of MFGM or supple-
mentation with bovine-derived MFGM mixtures enriched
in bioactive lipids, or isolated specific bioactive MFGM
components, may exert potential positive effects on skeletal
muscle structure and function in physiological settings of
development, growth and muscle regeneration/remodelling
(e.g. tissue injury/healing, exercise recovery, reloading
following disuse). Furthermore, the apparent positive effect
of MFGM supplementation on modulation of neuromus-
cular/synaptogenic development pathways may be indica-
tive of a potential therapeutic benefit of bovine MFGM or
composite molecules in settings of nerve-related muscle
dysfunction such as ageing and neuromuscular disease.
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